Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 30 of 30 entries
Sorted by: Best Match Show Resources per page
A case of the serotonin syndrome secondary to phenelzine monotherapy at therapeutic dosing.

Case reports in medicine

Malik A, Junglee N.
PMID: 25861278
Case Rep Med. 2015;2015:931963. doi: 10.1155/2015/931963. Epub 2015 Mar 16.

A 27-year-old Caucasian female with a history of depression was admitted to our local hospital with vague events that occurred a day before. This included an episode of dysarthria, and unsteadiness, followed by feeling generally unwell. Two weeks prior...

Cite
Malik A, Junglee N. A case of the serotonin syndrome secondary to phenelzine monotherapy at therapeutic dosing. Case Rep Med. 2015;2015:931963doi: 10.1155/2015/931963.
Malik, A., & Junglee, N. (2015). A case of the serotonin syndrome secondary to phenelzine monotherapy at therapeutic dosing. Case reports in medicine, 2015931963. https://doi.org/10.1155/2015/931963
Malik, A, and Junglee, N. "A case of the serotonin syndrome secondary to phenelzine monotherapy at therapeutic dosing." Case reports in medicine vol. 2015 (2015): 931963. doi: https://doi.org/10.1155/2015/931963
Malik A, Junglee N. A case of the serotonin syndrome secondary to phenelzine monotherapy at therapeutic dosing. Case Rep Med. 2015;2015:931963. doi: 10.1155/2015/931963. Epub 2015 Mar 16. PMID: 25861278; PMCID: PMC4378324.
Copy Download .nbib Format: NLM
Transdermal selegiline for the treatment of major depressive disorder.

Neuropsychiatric disease and treatment

Lee KC, Chen JJ.
PMID: 19300583
Neuropsychiatr Dis Treat. 2007;3(5):527-37.

Non-selective inhibition of monoamine oxidase (MAO) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects. In the US, the selegiline transdermal system (STS; EMSAM) is the first antidepressant transdermal delivery system to...

Cite
Lee KC, Chen JJ. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37
Lee, K. C., & Chen, J. J. (2007). Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatric disease and treatment, 3(5), 527-37.
Lee, Kelly C, and Chen, Jack J. "Transdermal selegiline for the treatment of major depressive disorder." Neuropsychiatric disease and treatment vol. 3,5 (2007): 527-37.
Lee KC, Chen JJ. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. PMID: 19300583; PMCID: PMC2656289.
Copy Download .nbib Format: NLM
MAO-inhibitors in Parkinson's Disease.

Experimental neurobiology

Riederer P, Laux G.
PMID: 22110357
Exp Neurobiol. 2011 Mar;20(1):1-17. doi: 10.5607/en.2011.20.1.1. Epub 2011 Mar 31.

Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's disease (PD). They have been used with or without levodopa (L-DOPA). Non-selective MAO-I due to their side-effect/adverse reaction profile, like tranylcypromine have limited use in the treatment...

Cite
Riederer P, Laux G. MAO-inhibitors in Parkinson's Disease. Exp Neurobiol. 2011;20(1):1-17doi: 10.5607/en.2011.20.1.1.
Riederer, P., & Laux, G. (2011). MAO-inhibitors in Parkinson's Disease. Experimental neurobiology, 20(1), 1-17. https://doi.org/10.5607/en.2011.20.1.1
Riederer, Peter, and Laux, Gerd. "MAO-inhibitors in Parkinson's Disease." Experimental neurobiology vol. 20,1 (2011): 1-17. doi: https://doi.org/10.5607/en.2011.20.1.1
Riederer P, Laux G. MAO-inhibitors in Parkinson's Disease. Exp Neurobiol. 2011 Mar;20(1):1-17. doi: 10.5607/en.2011.20.1.1. Epub 2011 Mar 31. PMID: 22110357; PMCID: PMC3213739.
Copy Download .nbib Format: NLM
Administration of supplemental L-tyrosine with phenelzine: a clinical literature review.

Clinical pharmacology : advances and applications

Hinz M, Stein A, Cole T, Ryan P.
PMID: 25092999
Clin Pharmacol. 2014 Jul 22;6:107-10. doi: 10.2147/CPAA.S67271. eCollection 2014.

The subject of this literature review is the alleged relationship between L-tyrosine, phenelzine, and hypertensive crisis. Phenelzine (Nardil(®)) prescribing information notes: "The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS)....

Cite
Hinz M, Stein A, Cole T, et al. Administration of supplemental L-tyrosine with phenelzine: a clinical literature review. Clin Pharmacol. 2014;6:107-10doi: 10.2147/CPAA.S67271.
Hinz, M., Stein, A., Cole, T., & Ryan, P. (2014). Administration of supplemental L-tyrosine with phenelzine: a clinical literature review. Clinical pharmacology : advances and applications, 6107-10. https://doi.org/10.2147/CPAA.S67271
Hinz, Marty, et al. "Administration of supplemental L-tyrosine with phenelzine: a clinical literature review." Clinical pharmacology : advances and applications vol. 6 (2014): 107-10. doi: https://doi.org/10.2147/CPAA.S67271
Hinz M, Stein A, Cole T, Ryan P. Administration of supplemental L-tyrosine with phenelzine: a clinical literature review. Clin Pharmacol. 2014 Jul 22;6:107-10. doi: 10.2147/CPAA.S67271. eCollection 2014. PMID: 25092999; PMCID: PMC4112771.
Copy Download .nbib Format: NLM
Optimal treatment of social phobia: systematic review and meta-analysis.

Neuropsychiatric disease and treatment

Canton J, Scott KM, Glue P.
PMID: 22665997
Neuropsychiatr Dis Treat. 2012;8:203-15. doi: 10.2147/NDT.S23317. Epub 2012 May 03.

This article proposes a number of recommendations for the treatment of generalized social phobia, based on a systematic literature review and meta-analysis. An optimal treatment regimen would include a combination of medication and psychotherapy, along with an assertive clinical...

Cite
Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;8:203-15doi: 10.2147/NDT.S23317.
Canton, J., Scott, K. M., & Glue, P. (2012). Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatric disease and treatment, 8203-15. https://doi.org/10.2147/NDT.S23317
Canton, John, et al. "Optimal treatment of social phobia: systematic review and meta-analysis." Neuropsychiatric disease and treatment vol. 8 (2012): 203-15. doi: https://doi.org/10.2147/NDT.S23317
Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;8:203-15. doi: 10.2147/NDT.S23317. Epub 2012 May 03. PMID: 22665997; PMCID: PMC3363138.
Copy Download .nbib Format: NLM
"Ping-pong gaze" secondary to monoamine oxidase inhibitor overdose.

Journal of pharmacology & pharmacotherapeutics

Attaway A, Sroujieh L, Mersfelder TL, Butler C, Ouellette D.
PMID: 27127395
J Pharmacol Pharmacother. 2016 Jan-Mar;7(1):34-7. doi: 10.4103/0976-500X.179360.

An infrequent manifestation of monoamine oxidase inhibitor (MAOI) toxicity is "ping-pong gaze" (PPG). We describe the case of a 26-year-old female who was found unresponsive after taking 40 tablets of phenelzine. On presentation to the hospital, her eyes were...

Cite
Attaway A, Sroujieh L, Mersfelder TL, et al. "Ping-pong gaze" secondary to monoamine oxidase inhibitor overdose. J Pharmacol Pharmacother. 2016;7(1):34-7doi: 10.4103/0976-500X.179360.
Attaway, A., Sroujieh, L., Mersfelder, T. L., Butler, C., & Ouellette, D. (2016). "Ping-pong gaze" secondary to monoamine oxidase inhibitor overdose. Journal of pharmacology & pharmacotherapeutics, 7(1), 34-7. https://doi.org/10.4103/0976-500X.179360
Attaway, Amy, et al. ""Ping-pong gaze" secondary to monoamine oxidase inhibitor overdose." Journal of pharmacology & pharmacotherapeutics vol. 7,1 (2016): 34-7. doi: https://doi.org/10.4103/0976-500X.179360
Attaway A, Sroujieh L, Mersfelder TL, Butler C, Ouellette D. "Ping-pong gaze" secondary to monoamine oxidase inhibitor overdose. J Pharmacol Pharmacother. 2016 Jan-Mar;7(1):34-7. doi: 10.4103/0976-500X.179360. PMID: 27127395; PMCID: PMC4831489.
Copy Download .nbib Format: NLM
Showing 25 to 30 of 30 entries